Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review. (Q38026582)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22799463%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22799463%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22799463%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

Sherry A Martin

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22799463%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Zvonko Milicevic

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22799463%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

language of work or name

English

0 references

publication date

16 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22799463%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

8 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22799463%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22799463%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

1463-1474

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22799463%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22799463%20AND%20SRC:MED&resulttype=core&format=json

A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe.

8 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Long term patterns of use after initiation of oral antidiabetic drug therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Beyond metformin: initiating combination therapy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Combining basal insulin analogs with glucagon-like peptide-1 mimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Standards of medical care in diabetes--2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Glucose variability is associated with intensive care unit mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Combination therapies with insulin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Weight beneficial treatments for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Exenatide therapy in insulin-treated type 2 diabetes and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

A cohort study of acute pancreatitis in relation to exenatide use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707190

10.1517/13543784.2012.707190

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22799463%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference